Michael Webster-Clark

Michael Webster-Clark

Auto-generated profile, based on publicly available information

Michael Webster-Clark

Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Division of Public Health Sciences, Winston Salem, NC, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2020 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
MWMichael Webster‐Clark
Michael Webster‐Clark
TSTil Stürmer
Til Stürmer
TWTiansheng Wang
Tiansheng Wang
KMKenneth Man
Kenneth Man
DMDanica Marinac‐Dabic
Danica Marinac‐Dabic
RGRobert J. Glynn
Robert J. Glynn

19 August 2022 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
EDEmilie D. Duchesneau
Emilie D. Duchesneau
BJBradford E. Jackson
Bradford E. Jackson
MWMichael Webster-Clark
Michael Webster-Clark
JLJennifer L. Lund
Jennifer L. Lund
KRKatherine E. Reeder-Hayes
Katherine E. Reeder-Hayes
PSPaula Strassle
Paula Strassle
Background: Studies evaluating the effects of cancer treatments are prone to immortal time bias that, if unaddressed, can lead to treatments appearing more beneficial than they are. Methods: To demonstrate the impact of immortal time bias, we compared results across several analytic approaches (dichotomous exposure, dichotomous exposure excluding immortal time, time-varying exposure, landmark analysis, clone-censor-weight method), using surgical resection among women with metastatic breast cancer as an example. All adult women diagnosed with incident metastatic breast cancer from 2013–2016 in the National Cancer Database were included. To quantify immortal time bias, we also conducted a simulation study where the “true” relationship between surgical resection and mortality was known. Results: 24,329 women (median age 61, IQR 51–71) were included, and 24% underwent surgical resection. The largest association between resection and mortality was observed when using a dichotomized exposure [HR, 0.54; 95% confidence interval (CI), 0.51–0.57], followed by dichotomous with exclusion of immortal time (HR, 0.62; 95% CI, 0.59–0.65). Results from the time-varying exposure, landmark, and clone-censor-weight method analyses were closer to the null (HR, 0.67–0.84). Results from the plasmode simulation found that the time-varying exposure, landmark, and clone-censor-weight method models all produced unbiased HRs (bias −0.003 to 0.016). Both standard dichotomous exposure (HR, 0.84; bias, −0.177) and dichotomous with exclusion of immortal time (HR, 0.93; bias, −0.074) produced meaningfully biased estimates. Conclusions: Researchers should use time-varying exposures with a treatment assessment window or the clone-censor-weight method when immortal time is present. Impact: Using methods that appropriately account for immortal time will improve evidence and decision-making from research using real-world data.

25 August 2020 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
MWMichael Webster-Clark
Michael Webster-Clark
ABAlexander Breskin
Alexander Breskin
Directed acyclic graphs (DAGs) have had a major impact on the field of epidemiology by providing straightforward graphical rules for determining when estimates are expected to lack causally interpretable internal validity. Much less attention has been paid, however, to what DAGs can tell researchers about effect measure modification and external validity. In this work, we describe 2 rules based on DAGs related to effect measure modification. Rule 1 states that if a variable, $P$, is conditionally independent of an outcome, $Y$, within levels of a treatment, $X$, then $P$ is not an effect measure modifier for the effect of $X$ on $Y$ on any scale. Rule 2 states that if $P$ is not conditionally independent of $Y$ within levels of $X$, and there are open causal paths from $X$ to $Y$ within levels of $P$, then $P$ is an effect measure modifier for the effect of $X$ on $Y$ on at least 1 scale (given no exact cancelation of associations). We then show how Rule 1 can be used to identify sufficient adjustment sets to generalize nested trials studying the effect of $X$ on $Y$ to the total source population or to those who did not participate in the trial.

10 August 2017 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
JHJin-Liern Hong
Jin-Liern Hong
MFMichele Jonsson Funk
Michele Jonsson Funk
RLRobert LoCasale
Robert LoCasale
SDSara E Dempster
Sara E Dempster
SCStephen R Cole
Stephen R Cole
TSTil Stürmer
Til Stürmer
Statins are indicated in patients with elevated levels of high-sensitivity C-reactive protein and normal low-density lipoprotein cholesterol based on results of the multicountry trial, Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) (2003–2008), but the benefit in real-world populations remains unknown. We sought to generalize JUPITER results to trial-eligible population using data from the UK Clinical Practice Research Datalink (CPRD), 2001–2014. We multiply imputed missing baseline characteristics for the CPRD population and selected the trial-eligible participants as the target population based on observed and imputed values. Trial participants were weighted to be representative of the CPRD population (n = 383,418) based on individual predicted probability of selection into the trial. Trial participants were also standardized to the CPRD population without missing values (n = 2,677). In JUPITER, rosuvastatin reduced cardiovascular risk with a 3-year risk difference of −2.0% (95% confidence interval (CI): −2.9, −1.1). The rosuvastatin effect was muted in the first 2 years but remained strong at 3 years after standardizing to the imputed CPRD population (3-year risk difference = −2.7%; 95% CI: −5.8, 0.4) and the CPRD population without missing data (3-year risk difference = −1.7%; 95% CI: −3.5, 0.1). The study serves as an illustration of possible approaches to understanding generalizability of trials using real-world databases given limitations due to missing data on inclusion/exclusion criteria.

1 February 2019 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
JHJin-Liern Hong
Jin-Liern Hong
MWMichael Webster-Clark
Michael Webster-Clark
MFMichele Jonsson Funk
Michele Jonsson Funk
TSTil Stürmer
Til Stürmer
SDSara E Dempster
Sara E Dempster
RLRobert LoCasale
Robert LoCasale
Our study explored the application of methods to generalize randomized controlled trial results to a target population without individual-level data. We compared 4 methods using aggregate data for the target population to generalize results from the international trial, Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), to a target population of trial-eligible patients in the UK Clinical Practice Research Datalink (CPRD). The gold-standard method used individual data from both the trial and CPRD to predict probabilities of being sampled in the trial and to reweight trial participants to reflect CPRD patient characteristics. Methods 1 and 2 used weighting methods based on simulated individual data or the method of moments, respectively. Method 3 weighted the trial’s subgroup-specific treatment effects to match the distribution of an effect modifier in CPRD. Method 4 calculated the expected absolute benefits in CPRD assuming homogeneous relative treatment effect. Methods based on aggregate data for the target population generally yielded results between the trial and gold-standard estimates. Methods 1 and 2 yielded estimates closest to the gold-standard estimates when continuous effect modifiers were represented as categorical variables. Although individual data or data on joint distributions remains the best approach to generalize trial results, these methods using aggregate data might be useful tools for timely assessment of randomized trial generalizability.

22 December 2020 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
MWMichael Webster-Clark
Michael Webster-Clark
RRRachael K Ross
Rachael K Ross
JLJennifer L Lund
Jennifer L Lund
New-user designs restricting to treatment initiators have become the preferred design for studying drug comparative safety and effectiveness using nonexperimental data. This design reduces confounding by indication and healthy-adherer bias at the cost of smaller study sizes and reduced external validity, particularly when assessing a newly approved treatment compared with standard treatment. The prevalent new-user design includes adopters of a new treatment who switched from or previously used standard treatment (i.e., the comparator), expanding study sample size and potentially broadening the study population for inference. Previous work has suggested the use of time-conditional propensity-score matching to mitigate prevalent user bias. In this study, we describe 3 “types” of initiators of a treatment: new users, direct switchers, and delayed switchers. Using these initiator types, we articulate the causal questions answered by the prevalent new-user design and compare them with those answered by the new-user design. We then show, using simulation, how conditioning on time since initiating the comparator (rather than full treatment history) can still result in a biased estimate of the treatment effect. When implemented properly, the prevalent new-user design estimates new and important causal effects distinct from the new-user design.